Martin Metzenmacher

Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome

Fibroblast Activation Protein–Directed Imaging Outperforms¹⁸F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer (<scp>ESPATUE</scp>)

Minimally invasive determination of pancreatic ductal adenocarcinoma ( <scp>PDAC</scp> ) subtype by means of circulating cell‐free <scp>RNA</scp>

Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNA

The clinical utility of <scp>cfRNA</scp> for disease detection and surveillance: A proof of concept study in non‐small cell lung cancer

[68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer

Comparison of early tumour-associated versus late deaths in patients with central or &gt;7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve

Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX).